# Fasting Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg

> **NCT00650273** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 54 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Azithromycin Tablets 600 mg
- **DRUG:** Zithromax® Tablets 600 mg

## Key facts

- **NCT ID:** NCT00650273
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2005-05
- **Final completion:** 2005-05
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00650273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00650273, "Fasting Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00650273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*